Note: This is an imagined future story, written as if a projected milestone has occurred. It is based on current trends and evidence, not confirmed events.
A research consortium has announced what independent reviewers are calling the first verified functional cure for type 1 diabetes — a milestone that, if confirmed at scale, would free millions of people from a lifetime of insulin dependency, continuous monitoring, and the slow accumulation of complications that have defined the disease for over a century.
Key projections
- Type 1 diabetes cure: A combined stem cell and immune-tolerance therapy has restored natural insulin production in a majority of trial participants, with no return to insulin dependency at the two-year follow-up mark.
- Global diabetes burden: By 2037 C.E., the number of people living with all forms of diabetes has surpassed 750 million worldwide, making this breakthrough one of the most consequential medical events in a generation.
- Regulatory pathway: Regulators in the U.S., E.U., and several high-burden countries are fast-tracking review, with conditional approvals expected within 18 months.
What changed
The path to this moment stretched back decades. Insulin itself was isolated in 1921 C.E., and for most of the century that followed, management — not cure — was the ceiling of ambition.
The field began shifting in earnest in the 2010s and 2020s. Hybrid closed-loop systems, sometimes called artificial pancreases, automated insulin delivery in real time. In 2022 C.E., the U.S. Food and Drug Administration approved teplizumab, the first drug shown to delay the onset of type 1 diabetes by modifying the T-cell activity responsible for destroying insulin-producing beta cells. A year later, a patient in China achieved insulin independence following stem cell-derived islet cell transplantation.
Each advance pointed toward the same two-part problem: how to replace the beta cells the immune system had destroyed, and how to stop the immune system from destroying the new ones.
The 2037 C.E. therapy solves both simultaneously. Stem cell-derived beta cells are introduced into the pancreas using a refined transplantation protocol. At the same time, a tolerogenic immune-cell therapy — developed from earlier work on engineered dendritic cells — reprograms the immune system to recognize the new beta cells as self, rather than targets.
The science behind the milestone
Type 1 diabetes is an autoimmune condition. The body’s own immune system attacks and destroys the beta cells in the pancreas that produce insulin. Without insulin, cells cannot absorb glucose, and blood sugar rises to levels that damage organs over time.
Earlier attempts at islet cell transplantation were hampered by two stubborn realities: donor scarcity and immune rejection. Stem cell science offered a solution to the first problem by providing an essentially unlimited source of lab-grown beta cells. The second problem — immune rejection — proved harder.
Researchers exploring tolerogenic cellular therapies found that engineered dendritic cells could promote regulatory T cells capable of suppressing the autoimmune attack. Early clinical trials in the 2020s suggested the approach was safe. Combining it with improved stem cell protocols was the conceptual leap that took years to execute.
The trial published this year involved participants who had lived with type 1 diabetes for an average of 11 years. Most had no measurable beta-cell function at enrollment. At 24 months post-treatment, the majority showed restored endogenous insulin production sufficient to maintain normal blood glucose without external insulin — a result the field has long considered the functional definition of a cure. This is one of many medical breakthroughs building toward a future where chronic autoimmune conditions are no longer lifelong sentences.
The unfinished work
The announcement has generated enormous excitement, but researchers and patient advocates are urging caution.
Trial participants were selected carefully — all had relatively recent-onset disease, no serious comorbidities, and access to the specialized centers running the protocol. Whether the therapy works as well for people who have lived with type 1 diabetes for 20 or 30 years, or for those with other health conditions, remains an open question.
Cost and access are the harder problem. The manufacturing process for personalized stem cell therapies remains expensive, and the immune-conditioning protocol requires infrastructure that does not exist in most lower-income countries. The World Health Organization has noted that the burden of diabetes falls disproportionately on low- and middle-income nations — the same places least likely to see early access to a treatment of this complexity and cost.
Type 2 diabetes, which accounts for the vast majority of the 750-million-plus cases worldwide, operates through a different mechanism entirely. This therapy addresses neither insulin resistance nor the broader metabolic conditions that drive type 2. Researchers are working on parallel tracks, but a cure for type 2 remains further away.
What this means for the people who waited
For the roughly 8 to 9 million people currently living with type 1 diabetes, the announcement lands with particular weight. The disease has required — depending on the era and the technology available — multiple daily injections, constant blood glucose monitoring, and the management of a condition that never fully yields to routine.
Research published in The Lancet has long documented the toll: increased risk of blindness, kidney failure, heart attack, and stroke, all compounding over decades of imperfect glucose control. The prospect of ending that accumulation of risk — not just managing it — is what makes this moment different from every advance that came before.
Advocacy groups are already pressing regulators to develop tiered pricing structures and technology-transfer agreements so that the therapy reaches patients in high-burden regions before a decade passes. The science, for once, is ahead of the system.
Diabetes research foundations that spent decades funding incremental progress are now pivoting to focus on implementation — how to manufacture the therapy at scale, train the specialists needed to deliver it, and monitor outcomes in populations the original trial did not include.
The cure exists, on paper and in the bodies of the people who received it. The question now is who gets it, and when.
Read more
For more on this story, see: Labiotech — Diabetes treatment and cure review
For more from Good News for Humankind, see:
- Renewables now make up at least 49% of global power capacity
- Global suicide rate has fallen by 40% since 1995
- The Good News for Humankind archive on medical breakthroughs
About this article
- 🤖 This article is AI-generated, based on a framework created by Peter Schulte.
- 🌍 It aims to be inspirational but clear-eyed, accurate, and evidence-based, and grounded in care for the Earth, peace and belonging for all, and human evolution.
- 💬 Leave your notes and suggestions in the comments below — I will do my best to review and implement where appropriate.
- ✉️ One verified piece of good news, one insight from Antihero Project, every weekday morning. Subscribe free.
More from the Archive of Human Genius
-
Share of children in extreme poverty drops below 1% for the first time
Child poverty could fall below 1% worldwide by 2047, a threshold never crossed in recorded history. The momentum is already visible: direct cash transfer programs reached about 2 billion people in recent years, up from roughly 1 billion in 2020. If the trend holds, hundreds of millions of children would grow up with a floor beneath them.
-
Global shipping industry reaches net-zero carbon emissions for the first time
Global shipping could reach net-zero emissions by 2046, if current momentum holds. The shift is already underway: green hydrogen costs fell more than 80% between 2020 and 2040, and major ports are racing to install zero-emission fueling. If it lands, an industry once seen as impossible to clean up becomes proof that the hardest problems are still solvable.
-
The U.S. surpasses 100 GW of offshore wind capacity for the first time
U.S. offshore wind could reach 100 gigawatts by the late 2040s, enough to power roughly 38 million homes. The pipeline already grew 53% in a single year as of 2025, and eleven states have set procurement targets totaling 84 GW. If the trajectory holds, it would mark one of the largest clean-energy buildouts in American history.
